Palatin Technologies, Inc. (NYSEAMERICAN:PTN) has earned an average recommendation of “Buy” from the six research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $4.00.
A number of equities research analysts have commented on the stock. Zacks Investment Research upgraded shares of Palatin Technologies from a “sell” rating to a “hold” rating in a research note on Wednesday, July 18th. HC Wainwright set a $5.00 target price on shares of Palatin Technologies and gave the stock a “buy” rating in a research note on Monday, June 4th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Palatin Technologies in a research note on Wednesday, June 27th. They set a “buy” rating and a $3.00 target price on the stock.
NYSEAMERICAN PTN traded down $0.02 on Monday, reaching $1.01. 1,043,921 shares of the stock were exchanged, compared to its average volume of 1,705,893. Palatin Technologies has a one year low of $0.58 and a one year high of $1.59.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN grew its holdings in shares of Palatin Technologies by 79,946.5% in the fourth quarter. Wells Fargo & Company MN now owns 160,093 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 159,893 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Palatin Technologies by 1,031.6% in the fourth quarter. Millennium Management LLC now owns 272,717 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 248,617 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Palatin Technologies by 22.6% in the first quarter. Northern Trust Corp now owns 333,277 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 61,351 shares in the last quarter. Tibra Equities Europe Ltd purchased a new position in shares of Palatin Technologies in the first quarter valued at $422,000. Finally, Citadel Advisors LLC grew its holdings in shares of Palatin Technologies by 130.8% in the first quarter. Citadel Advisors LLC now owns 173,790 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 98,483 shares in the last quarter.
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD).
See Also: What does RSI mean?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.